

## **Ono Supports TNFD Recommendations and Discloses Information Aligned with TNFD Framework**

Osaka, Japan, August 8, 2024 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino, “Ono”) today announced that it has expressed its support for the final recommendations on information disclosure published in September 2023 by a Taskforce on Nature-related Financial Disclosures (TNFD)<sup>\*1</sup> and registered as a TNFD adopter<sup>\*2</sup> in July 2024. In addition, Ono prepared for disclosure of the information in line with the TNFD framework while confirming the assessment of dependences and impacts on nature in our business activities, and disclosed the information including the identified nature-related risks and opportunities with their countermeasures.

For details, please refer to our company website, “[Information of disclosure based on the TNFD recommendations.](#)”



Based on the medium- and long-term environmental vision, ECO VISION 2050 (Environment Challenging Ono Vision 2050), Ono has been committed to reducing greenhouse gas emissions, water usage and waste associated with our business activities for “Realization of a decarbonized society,” “Realization of a water recycling society,” and “Realization of a resource recycling society.” In addition to the above global environmental initiatives, we supported the TNFD recommendations in order to accelerate our efforts in biodiversity and have disclosed the information this time. We plan to continue to regularly review and update the nature-related risks and opportunities.

Ono continues to contribute to society by discovering and developing innovative pharmaceutical products, and will promote our efforts further to minimize the environmental burden in overall business activities, in order to contribute to the realization of “Nature Positive”<sup>\*3</sup> initiative.

<sup>\*1</sup> TNFD: Following the Taskforce on Climate-related Financial Disclosures (TCFD), TNFD is a global initiative established in June 2021 to promote “nature positive” efforts aiming to reverse and restore the declining tendency in biodiversity. For details, please visit following website (<https://tnfd.global/>).

<sup>\*2</sup> TNFD Adopter: Companies or organizations that have expressed their intention to start to make disclosures aligned with the TNFD recommendations in their corporate reporting by the financial year 2024 (or earlier) or 2025. For the companies or organizations expressed their intention, please visit the following website (<https://tnfd.global/engage/tnfd-adopters-list/>).

<sup>\*3</sup> Nature Positive: To halt and reverse biodiversity loss to put nature on a path to recovery. At the 15th Conference of the Parties to the Convention on Biological Diversity in 2022, the mission of taking urgent action to realize nature positive initiative by 2030 was adopted.

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

[public\\_relations@ono-pharma.com](mailto:public_relations@ono-pharma.com)